|
|
|
| Risk factors of deep vein thrombosis before clinical intervention in ovarian malignant tumors |
| LIANG Lingyun ZHAO Junda LIN Lin |
| Department of Gynecology, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi 830054, China |
|
|
|
Abstract Objective To explore the risk factors of deep vein thrombosis before clinical intervention in ovarian malignant tumor. Methods A total of 110 ovarian malignant tumor patients in the First Affiliated Hospital of Xinjiang Medical University from January 2017 June to 2019 March were selected. Before clinical intervention, the ovarian tumor marker carbohydrate antigen CA125, human epididymal protein HE4, plasma D-dimer (DD), and gynecological B-ultrasound and other related examinations were compared. The occurrence and risk factors of deep venous thrombosis in untreated ovarian malignant tumors were analyzed. Results Before the clinical intervention, the study population developed deep vein thrombosis in 17 patients, seven cases of ovarian serous adenocarcinoma, three cases of clear cell carcinoma, and three cases of undifferentiated cancer were included. Among them, advanced ovarian malignant tumors accounted for 94.2%, and 52.9% of patients were accompanied by a large amount of ascites, and 88.2% of patients with deep vein thrombosis had no obvious clinical symptoms. When the plasma DD level was ≥2000 ng/mL, the incidence of thrombosis was significantly higher than that of the other groups, and the differences were statistically significant (P ＜ 0.05). There were no significant differences in the occurrence of deep vein thrombosis in different ages, nationalities, body mass index and ascites, tumor markers and special pathological types (P ＞ 0.05); comparisons of large tumor size, late tumor stage and high levels of plasma DD showed statistical differences significance (P ＞ 0.05). In multivariate analysis, plasma DD level ≥1000 ng/mL was a risk factor for deep vein thrombosis in untreated ovarian malignant tumors (OR ＞ 1, P ＜ 0.05). Conclusion The risk factor for deep vein thrombosis in untreated malignant ovarian tumors is significantly increased the levels of DD.
|
|
|
|
|
|
[1] Timp JF，Braekkan SK，Versteeg HH，et al. Epidemiology of cancer associated venous thrombosis [J]. Blood，2013， 122：1712-1723.
[2] Trujillo-Santos J，Nieto JA，Tiberio G，et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism [J]. Thromb Haemost，2008，100（3）：435-439.
[3] Chew HK，Wun T，Harvey DJ，et al. Incidence of venous thromboembolism and its effect on survival patients with common cancers [J]. Arch Intern Med，2006，166（4）：458-464.
[4] Gould MK，Garcia DA，Wren SM，et al. Prevention of VTE in nonorthopedic surgical patients：Antithrombotic Therapy and Prevention of Thrombosis，9th ed：American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J]. Chest，2012，141（5）：1369.
[5] Li N，Zhang FB，Li BJ，et al. Combination of Preoperative D-Dimer and Platelet Distribution width Predicts Postoperative Deep Venous Thrombosis in Patients with Cervical Carcinoma [J]. Asian Pac J Cancer Prev，2019，20（4）：1025-1029.
[6] Kahr HS，Christiansen OB，Hogdall C，et al. Endometrial cancer does not increase the 30-day risk of venous thromboembolism following hysterectomy compared to benign disease. A Danish National Cohort Study [J]. Gynecol Oncol，2019，155（1）：112-118.
[7] Prat J. Staging classification for cancer of the ovary，fallopian tube，and peritoneum [J]. Int J Gynecol Obstet，2015，126（1）：171-174.
[8] Ebina Y，Uchiyama M，Imafuku H，et al. Risk factors for deep venous thrombosis in women with ovarian cancer [J]. Medicine，2018，97（23）：e11009.
[9] 胡月，唐冬.合并深静脉血栓形成对卵巢癌预后的影响[J].中国医药导报，2018，15（8）：96-99.
[10] Sandén P，Svensson PJ，Sj?觟lander A. Venous thromboembolism and cancer risk [J]. J Thromb Thrombolysis，2017，43（1）：68-73.
[11] Vahid DM，Ahmari S，Alipour S，et al. The comparison of plasma D-dimer levels in benign and malignant tumors of cervix，ovary and uterus [J]. Int J Hematol Oncol Stem Cell Res，2015，9（3）：107-111.
[12] 吴雪峰，李晓鸥，张晓伟.卵巢癌患者血浆Ｄ－二聚体水平与静脉血栓栓塞的关系研究[J].中国实验诊断学，2016，20（10）：1718-1720.
[13] Ay C，Dunkler D，Pirker R，et al. High D-dimer levels are associated with poor prognosis in cancer patients [J]. Haematologica，2012，97（8）：1158-1164.
[14] 马爱矿，高丽华，王敏，等.HE4、CA125和CA199联合D-二聚体检测在卵巢癌早期诊断中的应用[J].中国肿瘤临床与康复，2019，26（7）：793-795.
[15] 周琦，徐伏兰，张蔚.卵巢癌患者术后深静脉血栓形成的Logistic回归分析[J].武汉大学学报：医学版，2019， 40（5）：747-751.
[16] Takasaki K，Miyamoto M，Takano M，et al. Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma [J]. Int J Clin Oncol，2019，24（10）：1273-1283.
[17] Abu Saadeh F，Norris L，O′Toole S，et al. Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk [J]. Thromb Res，2013，132：627-634.
[18] Sakurai M，Matsumoto K，Gosho M，et al. Expression of tissue factor in epithelial ovarian carcinoma is involved in the development of venous thromboembolism [J]. Int J Gynecol Cancer，2017，27（1）：37-43.
[19] 梁凌云，陈艳霞，何艳.高水平D-二聚体在血栓性疾病诊断中的临床价值[J].检验医学与临床，2019，16（10）：1328-1331.
[20] Kearon C，Akl EA，Ornelas J，et al. Antithrombotic therapy for VTE disease：CHEST guideline and expert panel report [J]. Chest，2016，149（2）：315-352. |
|
|
|
